{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ALK-positive+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=2",
    "query": {
      "condition": "ALK-positive Non-small Cell Lung Cancer (NSCLC)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ALK-positive+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:16:37.478Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02299505",
      "title": "Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ceritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2015-04-09",
      "completion_date": "2020-03-06",
      "has_results": false,
      "last_update_posted_date": "2022-02-09",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 7,
      "location_summary": "Fayetteville, Arkansas • Loma Linda, California • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Belleville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02299505"
    },
    {
      "nct_id": "NCT05144997",
      "title": "Lorlatinib Continuation Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Non-Small-Cell Lung Cancer",
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2021-12-28",
      "completion_date": "2026-12-28",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05144997"
    },
    {
      "nct_id": "NCT06765109",
      "title": "Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Anaplastic Lymphoma Kinase-positive"
      ],
      "interventions": [
        {
          "name": "Neladalkib (NVL-655)",
          "type": "DRUG"
        },
        {
          "name": "Alectinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvalent Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2025-07-17",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 21,
      "location_summary": "Glendale, Arizona • Newport Beach, California • Orange, California + 17 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06765109"
    },
    {
      "nct_id": "NCT01828112",
      "title": "LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ceritinib",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 231,
      "start_date": "2013-06-28",
      "completion_date": "2023-11-10",
      "has_results": true,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 13,
      "location_summary": "Fayetteville, Arkansas • Hollywood, Florida • Jacksonville, Florida + 10 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Marywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828112"
    },
    {
      "nct_id": "NCT04146571",
      "title": "Expanded Access to Ensartinib for Participants With ALK+ NSCLC",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "ALK Gene Rearrangement Positive"
      ],
      "interventions": [
        {
          "name": "Ensartinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xcovery Holdings, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-10-20",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Bethesda, Maryland • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04146571"
    },
    {
      "nct_id": "NCT02201992",
      "title": "Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ALK Gene Rearrangement",
        "ALK Gene Translocation",
        "ALK Positive",
        "Stage IB Non-Small Cell Lung Carcinoma AJCC v7",
        "Stage II Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIA Non-Small Cell Lung Carcinoma AJCC v7",
        "Stage IIB Non-Small Cell Lung Carcinoma AJCC v7",
        "Stage IIIA Non-Small Cell Lung Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2015-03-23",
      "completion_date": "2036-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 1613,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02201992"
    },
    {
      "nct_id": "NCT01970865",
      "title": "A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC"
      ],
      "interventions": [
        {
          "name": "PF-06463922",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 364,
      "start_date": "2014-01-08",
      "completion_date": "2023-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 32,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Orange, California + 14 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01970865"
    },
    {
      "nct_id": "NCT04351334",
      "title": "Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Small-Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Alectinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2020-03-01",
      "completion_date": "2022-11-01",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04351334"
    },
    {
      "nct_id": "NCT07140016",
      "title": "A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)",
        "Anaplastic Lymphoma Kinase (ALK) Positive"
      ],
      "interventions": [
        {
          "name": "gilteritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-22",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 8,
      "location_summary": "Orange, California • Atlanta, Georgia • Peoria, Illinois + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07140016"
    },
    {
      "nct_id": "NCT03088930",
      "title": "Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Nonsmall Cell"
      ],
      "interventions": [
        {
          "name": "Crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 3,
      "start_date": "2017-12-13",
      "completion_date": "2021-01-13",
      "has_results": true,
      "last_update_posted_date": "2022-02-11",
      "last_synced_at": "2026-05-22T08:16:37.478Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03088930"
    }
  ]
}